Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The multikinase inhibitor EC-70124 synergistically increased the antitumor activity of doxorubicin in sarcomas

  • Estupiñán, Óscar
  • Santos, Laura
  • Rodríguez, Aída
  • Fernández-Nevado, Lucía
  • Costales, Paula
  • Pérez-Escuredo, Jhudit
  • Hermosilla, María Ana
  • Oro, Patricia
  • Rey, Verónica
  • Tornín, Juan
  • Allonca, Eva
  • Fernández-García, María Teresa
  • Álvarez-Fernández, Carlos
  • Braña, Alejandro
  • Astudillo, Aurora
  • Menéndez, Sofía T.
  • Moris, Francisco
  • Rodríguez, René
Cytotoxic drugs like doxorubicin remain as the most utilized agents in sarcoma treatment. However, advanced sarcomas are often resistant, thus stressing the need for new therapies aimed to overcome this resistance. Multikinase inhibitors provide an efficient way to target several pro-tumorigenic pathways using a single agent and may constitute a valuable strategy in the treatment of sarcomas, which frequently show an aberrant activation of pro-tumoral kinases. Therefore, we studied the antitumor activity of EC-70124, an indolocarbazole analog that have demonstrated a robust ability to inhibit a wide range of pro-survival kinases. Evaluation of the phospho-kinase profile in cell-of-origin sarcoma models and/or sarcoma primary cell lines evidenced that PI3K/AKT/mTOR, JAK/STAT or SRC were among the most highly activated pathways. In striking contrast with the structurally related drug midostaurin, EC-70124 efficiently prevented the phosphorylation of these targets and robustly inhibited proliferation through a mechanism associated to the induction of DNA damage, cell cycle arrest and apoptosis. In addition, EC-70124 was able to partially reduce tumor growth in vivo. Importantly, this compound inhibited the expression and activity of ABC efflux pumps involved in drug resistance. In line with this ability, we found that the combined treatment of EC-70124 with doxorubicin resulted in a synergistic cytotoxic effect in vitro and an increased antitumor activity of this cytotoxic drug in vivo. Altogether, these results uncover the capability of the novel multikinase inhibitor EC-70124 to counteract drug resistance in sarcoma and highlight its therapeutic potential when combined with current treatments, This work was supported by the Agencia Estatal de Investigación (AEI) [MICINN/Fondo Europeo de Desarrollo Regional (FEDER) (RTC2016-4603-1 to EntreChem SL and SAF-2016-75286-R to R.R.), ISC III/FEDER [Miguel Servet Program] (CPII16/00049 to R.R.), Sara Borrell Program (CD16/00103 to S-T.M.) and Consorcio CIBERONC (CB16/12/00390)] and the Plan de Ciencia Tecnología e Innovación del Principado de Asturias (GRUPIN14-003). We want to particularly acknowledge for its collaboration, the Principado de Asturias BioBank (PT17/0015/0023), financed jointly by Servicio de Salud del Principado de Asturias, Instituto de Salud Carlos III and Fundación Bancaria Cajastur and integrated in the Spanish National Biobanks Network., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models

  • Martínez-Cruzado, Lucía
  • Tornín, Juan
  • Rodríguez, Aída
  • Santos, Laura
  • Allonca, Eva
  • Fernández-Garcia, María Teresa
  • Astudillo, Aurora
  • García-Pedrero, Juana María
  • Rodríguez, René
Trabectedin has been approved for second-line treatment of soft tissue sarcomas. However, its efficacy to target sarcoma initiating cells has not been addressed yet. Here, we used pioneer models of myxoid/round cell liposarcoma (MRCLS) and undifferentiated pleomorphic sarcoma (UPS) developed from transformed human mesenchymal stromal/stem cells (MSCs) to evaluate the effect of trabectedin in the cell type responsible for initiating sarcomagenesis and their derived cancer stem cells (CSC) subpopulations. We found that low nanomolar concentrations of trabectedin efficiently inhibited the growth of sarcoma-initiating cells, induced cell cycle arrest, DNA damage and apoptosis. Interestingly, trabectedin treatment repressed the expression of multiple genes responsible for the development of the CSC phenotype, including pluripotency factors, CSC markers and related signaling pathways. Accordingly, trabectedin induced apoptosis and reduced the survival of CSC-enriched tumorsphere cultures with the same efficiency that inhibits the growth of bulk tumor population. In vivo, trabectedin significantly reduced the mitotic index of MRCLS xenografts and inhibited tumor growth at a similar extent to that observed in doxorubicin-treated tumors. Combination of trabectedin with campthotecin (CPT), a chemotherapeutic drug that shows a robust anti-tumor activity when combined with alkylating agents, resulted in a very strong synergistic inhibition of tumor cell growth and highly increased DNA damage and apoptosis induction. Importantly, the enhanced anti-tumor activity of this combination was also observed in CSC subpopulations. These data suggest that trabectedin and CPT combination may constitute a novel strategy to effectively target both the cell-of-origin and CSC subpopulations in sarcoma., This work was supported by the Agencia Estatal de Investigación (AEI) [MINECO/Fondo Europeo de Desarrollo Regional (FEDER) (SAF-2013-42946-R and SAF-2016-75286-R to R.R.), ISC III/FEDER (Miguel Servet Program CP11/ 00024 and CPII16/00049 to R.R. and PI13/00259 and PI16/00280 to J.M.G-P) and Consorcio CIBERONC CB16/12/00390 to R.R and J.M.G-P)] and the Plan de Ciencia Tecnología e Innovación del Principado de Asturias (GRUPIN14–003) to R.R and J.M.G-P., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

FUS-CHOP Promotes Invasion in Myxoid Liposarcoma through a SRC/FAK/RHO/ROCK-Dependent Pathway

  • Tornín, Juan
  • Hermida-Prado, Francisco
  • Padda, Ranjit Singh
  • González, M. Victoria
  • Álvarez-Fernández, Carlos
  • Rey, Verónica
  • Martínez-Cruzado, Lucía
  • Estupiñán, Óscar
  • Menéndez, Sofía T.
  • Fernández-Nevado, Lucía
  • Astudillo, Aurora
  • Rodrigo, Juan P.
  • Lucien, Fabrice
  • Kim, Yohan
  • Leong, Hon S.
  • García-Pedrero, Juana María
  • Rodríguez, René
Deregulated SRC/FAK signaling leads to enhanced migration and invasion in many types of tumors. In myxoid and round cell liposarcoma (MRCLS), an adipocytic tumor characterized by the expression of the fusion oncogene FUS-CHOP, SRC have been found as one of the most activated kinases. Here we used a cell-of-origin model of MRCLS and an MRCLS cell line to thoroughly characterize the mechanisms of cell invasion induced by FUS-CHOP using in vitro (3D spheroid invasion assays) and in vivo (chicken chorioallantoic membrane model) approaches. FUS-CHOP expression activated SRC-FAK signaling and increased the invasive ability of MRCLS cells. In addition, FAK expression was found to significantly correlate with tumor aggressiveness in sarcoma patient samples. The involvement of SRC/FAK activation in FUS-CHOP–mediated invasion was further confirmed using the SRC inhibitor dasatinib, the specific FAK inhibitor PF-573228, and FAK siRNA. Notably, dasatinib and PF573228 could also efficiently block the invasion of cancer stem cell subpopulations. Downstream of SRC/FAK signaling, we found that FUS-CHOP expression increases the levels of the RHO/ROCK downstream effector phospho-MLC2 (T18/S19) and that this activation was prevented by dasatinib or PF573228. Moreover, the ROCK inhibitor RKI-1447 was able to completely abolish invasion in FUS-CHOP–expressing cells. These data uncover the involvement of SRC/FAK/RHO/ROCK signaling axis in FUS-CHOP–mediated invasion, thus providing a rationale for testing inhibitors of this pathway as potential novel antimetastatic agents for MRCLS treatment., This work was supported by the Agencia Estatal de Investigación (AEI) [MINECO/Fondo Europeo de Desarrollo Regional (FEDER) (SAF-2013-42,946-R and SAF-2016-75,286-R to R.R.), ISC III/FEDER (Miguel Servet II Program CPII16/00049 to R.R. and PI13/00259 and PI16/00280 to J.M.G-P) and Consorcio CIBERONC CB16/12/00390 to J.P.R)] and the Plan de Ciencia Tecnología e Innovación del Principado de Asturias (GRUPIN14-003) to J. P. R. H. S. L. is supported by Prostate Cancer Canada Rising Star Grant (RS2016-1011)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Impaired condensin complex and Aurora B kinase underlie mitotic and chromosomal defects in hyperdiploid B-cell ALL

  • Molina, Oscar
  • Vinyoles, Meritxell
  • Granada, Isabel
  • Roca-Ho, Heleia
  • Gutierrez-Agüera, Francisco
  • Valledor, Luis
  • López-López, Carlos M.
  • Rodríguez-González, Pablo
  • Trincado, Juan L.
  • Menéndez, Sofía T.
  • Pal, Deepali
  • Ballerini, Paola
  • den Boer, Monique L.
  • Plensa, Isabel
  • Mar Perez-Iribarne, M.
  • Rodríguez-Perales, Sandra
  • Calasanz, María José
  • Ramírez-Orellana, Manuel
  • Rodríguez, René
  • Camós, Mireia
  • Calvo, Maria V.
  • Bueno, Clara
  • Menéndez, Pablo
B-cell acute lymphoblastic leukemia (ALL; B-ALL) is the most common pediatric cancer, and high hyperdiploidy (HyperD) identifies the most common subtype of pediatric B-ALL. Despite HyperD being an initiating oncogenic event affiliated with childhood B-ALL, the mitotic and chromosomal defects associated with HyperD B-ALL (HyperD-ALL) remain poorly characterized. Here, we have used 54 primary pediatric B-ALL samples to characterize the cellular-molecular mechanisms underlying the mitotic/chromosome defects predicated to be early pathogenic contributors in HyperD-ALL. We report that HyperD-ALL blasts are low proliferative and show a delay in early mitosis at prometaphase, associated with chromosome-alignment defects at the metaphase plate leading to robust chromosome-segregation defects and nonmodal karyotypes. Mechanistically, biochemical, functional, and mass-spectrometry assays revealed that condensin complex is impaired in HyperD-ALL cells, leading to chromosome hypocondensation, loss of centromere stiffness, and mislocalization of the chromosome passenger complex proteins Aurora B kinase (AURKB) and Survivin in early mitosis. HyperD-ALL cells show chromatid cohesion defects and an impaired spindle assembly checkpoint (SAC), thus undergoing mitotic slippage due to defective AURKB and impaired SAC activity, downstream of condensin complex defects. Chromosome structure/condensation defects and hyperdiploidy were reproduced in healthy CD34+ stem/progenitor cells upon inhibition of AURKB and/or SAC. Collectively, hyperdiploid B-ALL is associated with a defective condensin complex, AURKB, and SAC., This work was supported by the European Research Council (CoG-2014-646903 [P.M.]), the Spanish Ministry of Economy and Competitiveness (SAF-2016-80481-R [P.M.]), the Asociación Española Contra el Cáncer (AECC-CI-2015), and the ISCIII (PI17/01028) (C.B.). The authors also acknowledge support from Fundación Leo Messi and the Fundación Uno entre Cienmil. O.M. was supported by a Lady Tata Memorial Trust (2017) and a “Beatriu de Pinós” postdoctoral fellowship (2018-2019) from Generalitat de Catalunya. D.P. was supported by an NC3Rs fellowship and a Children’s Cancer and Leukemia Group (CCLG) project grant. This work was also supported by the Spanish Ministry of Economy and Competitiveness (SAF-2016-75286-R [R.R.]), the ISCIII/FEDER (Miguel Servet Program CPII16/00049 [R.R.], Sara Borrell Program CD16/00103 [S.T.M.], and PI16/00280), and Consorcio CIBERONC (CB16/12/00390)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

SOX2 Expression and Transcriptional Activity Identifies a Subpopulation of Cancer Stem Cells in Sarcoma with Prognostic Implications

  • Menéndez, Sofía T.
  • Rey, Verónica
  • Martínez-Cruzado, Lucía
  • González, M. Victoria
  • Morales-Molina, Álvaro
  • Santos, Laura
  • Blanco, Verónica
  • Alvarez, Carlos
  • Estupiñán, Óscar
  • Allonca, Eva
  • Rodrigo, Juan Pablo
  • García-Castro, Javier
  • García-Pedrero, Juana María
  • Rodríguez, René
Stemness in sarcomas is coordinated by the expression of pluripotency factors, like SOX2, in cancer stem cells (CSC). The role of SOX2 in tumor initiation and progression has been well characterized in osteosarcoma. However, the pro-tumorigenic features of SOX2 have been scarcely investigated in other sarcoma subtypes. Here, we show that SOX2 depletion dramatically reduced the ability of undifferentiated pleomorphic sarcoma (UPS) cells to form tumorspheres and to initiate tumor growth. Conversely, SOX2 overexpression resulted in increased in vivo tumorigenicity. Moreover, using a reporter system (SORE6) which allows to monitor viable cells expressing SOX2 and/or OCT4, we found that SORE6+ cells were significantly more tumorigenic than the SORE6- subpopulation. In agreement with this findings, SOX2 expression in sarcoma patients was associated to tumor grade, differentiation, invasive potential and lower patient survival. Finally, we studied the effect of a panel of anti-tumor drugs on the SORE6+ cells of the UPS model and patient-derived chondrosarcoma lines. We found that the mithramycin analogue EC-8042 was the most efficient in reducing SORE6+ cells in vitro and in vivo. Overall, this study demonstrates that SOX2 is a pro-tumorigenic factor with prognostic potential in sarcoma. Moreover, SORE6 transcriptional activity is a bona fide CSC marker in sarcoma and constitutes an excellent biomarker for evaluating the efficacy of anti-tumor treatments on CSC subpopulations., This work was supported by the Agencia Estatal de Investigación (AEI) [MINECO/Fondo Europeo de Desarrollo Regional (FEDER) (SAF-2016-75286-R to R.R.), ISC III/FEDER (Miguel Servet Program CPII16/00049 to R.R., Sara Borrell Program CD16/00103 to S.T.M. and PI16/00280 and PI19/00560 to J.M.G.-P.) and Consorcio CIBERONC CB16/12/00390)] and the Plan de Ciencia Tecnología e Innovación del Principado de Asturias/FEDER (IDI/2018/155) to J.P.R. and Predoctoral Fellowship Severo Ochoa (BP-17-108) to O.E., Peer reviewed